Turning data into treatments for rare diseases
Posted by
17-Dec-2015
Next generation sequencing (NGS) allows scientists to understand our DNA like never before. It has the potential to improve diagnosis and treatment of diseases – including conditions which are rare or complex.
Whereas the Human Genome Project took years to complete and cost billions of euro, NGS is dramatically quicker and cheaper. This exciting technology is opening the door to a much deeper understanding of the human genome.
When the Human Genome Project was launched, the technical challenge of mapping the genome was enormous. However, that hurdle has now been cleared and NGS is generating large amounts of data.
The challenge now is to make sense of all of this information. To do this, we need to be able to move from statistics to analytics and from data to knowledge, analysing and interpreting NGS data in a manner that allows us to make informed decisions on what might, or might not, be a relevant target or mechanism to pursue.
To further out work in this area, UCB is supporting a rare disease research project with Congenica, a leading developer of genome analytics and clinical interpretation technologies. This partnership brings together the power of NGS with UCB’s drug discovery capacity.
UCB’s goal is to transform this insight into first-in-class therapies that dramatically benefit the lives of patients with unmet medical need in our core therapeutic areas of autoimmune and inflammatory diseases, and diseases of the Central Nervous System.
Through this project, Congenica and UCB hope to make significant advances that will positively impact patients’ lives.
Whereas the Human Genome Project took years to complete and cost billions of euro, NGS is dramatically quicker and cheaper. This exciting technology is opening the door to a much deeper understanding of the human genome.
When the Human Genome Project was launched, the technical challenge of mapping the genome was enormous. However, that hurdle has now been cleared and NGS is generating large amounts of data.
The challenge now is to make sense of all of this information. To do this, we need to be able to move from statistics to analytics and from data to knowledge, analysing and interpreting NGS data in a manner that allows us to make informed decisions on what might, or might not, be a relevant target or mechanism to pursue.
To further out work in this area, UCB is supporting a rare disease research project with Congenica, a leading developer of genome analytics and clinical interpretation technologies. This partnership brings together the power of NGS with UCB’s drug discovery capacity.
UCB’s goal is to transform this insight into first-in-class therapies that dramatically benefit the lives of patients with unmet medical need in our core therapeutic areas of autoimmune and inflammatory diseases, and diseases of the Central Nervous System.
Through this project, Congenica and UCB hope to make significant advances that will positively impact patients’ lives.
Leave a Comment